Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement

Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision's ARCUS® genome-editing technology DURHAM, N.C. and GAITHERSBURG, Md., Nov. 14, 2018 -- (Healthca... Biopharmaceuticals, Oncology, Licensing MaxCyte, Precision BioSciences, Flow Electroporation, ARCUS genome-editing
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news